藥明康德發布2022年度業(ye)(ye)(ye)績。營業(ye)(ye)(ye)收入(ru)(ru)(ru)同(tong)比強(qiang)勁增(zeng)長(chang)(chang)71.8%至393.55億(yi)(yi)元(yuan)(yuan)。其中，化學業(ye)(ye)(ye)務(WuXi Chemistry)收入(ru)(ru)(ru)288.50億(yi)(yi)元(yuan)(yuan)，同(tong)比增(zeng)長(chang)(chang)104.8%。測試業(ye)(ye)(ye)務(WuXi Testing)收入(ru)(ru)(ru)57.19億(yi)(yi)元(yuan)(yuan)，同(tong)比增(zeng)長(chang)(chang)26.4%。生物(wu)學業(ye)(ye)(ye)務(WuXi Biology)收入(ru)(ru)(ru)24.75億(yi)(yi)元(yuan)(yuan)，同(tong)比增(zeng)長(chang)(chang)24.7%。細胞及基因(yin)療法CTDMO業(ye)(ye)(ye)務(WuXi ATU)收入(ru)(ru)(ru)13.08億(yi)(yi)元(yuan)(yuan)，同(tong)比增(zeng)長(chang)(chang)27.4%。國內新藥研發服務部(WuXi DDSU)收入(ru)(ru)(ru)9.70億(yi)(yi)元(yuan)(yuan)，同(tong)比下降(jiang)22.5%。歸屬于上市公司股東(dong)的凈(jing)利潤88.14億(yi)(yi)元(yuan)(yuan)，同(tong)比增(zeng)長(chang)(chang)72.9%。(醫藥健聞)